Strasbourg-based Dreampath Diagnostics, a HealthTech firm targeted on digitising workflows in anatomical pathology laboratories, in the present day introduced a progress funding from Summit Companions.
Whereas monetary phrases of the transaction weren’t disclosed, the funding will assist the corporate’s plans to speed up world progress, scale operations and develop its industrial attain and product portfolio.
“Pathology labs are a important a part of the worldwide healthcare ecosystem, but many nonetheless depend on handbook, error-prone processes for pattern archiving and retrieval,” stated Pablo Jordan, CEO and Co-founder of Dreampath Diagnostics. “Our mission is to enhance the effectivity and accuracy of those workflows by automation and digital traceability, permitting labs to supply sufferers with sooner and safer diagnostics. We’re proud to accomplice with Summit to assist us scale our affect and attain extra sufferers all over the world.”
Based in 2012, Dreampath presents a patented suite of traceability options and consumables designed to automate and digitally rework the archiving and retrieval of tissue samples in pathology labs.
The corporate’s patented options mix purpose-built scanners, software program and consumables to allow automated and error-free archiving and speedy retrieval of tissue samples, serving to labs speed up diagnostics, enhance accuracy, and compliance.
As we speak, the corporate manages greater than 250 million samples throughout over 500 labs in practically 40 international locations, serving a broad vary of healthcare organizations, from hospitals and analysis establishments to industrial laboratories and most cancers facilities.
Dreampath’s integrated platform is protected by greater than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to assist eradicate the chance of affected person pattern loss. The corporate’s expertise is tailor-made to particular phases of the pathology course of and works with Dreampath’s proprietary software program and consumables.
This closed-loop system reportedly helps labs archive and retrieve tissue samples with pace and precision, with a concentrate on enhancing pattern traceability whereas lowering handbook errors, retrieval occasions and operational burden.
Clients utilizing the system have reported significant optimistic outcomes, noting an 83% discount in time spent archiving tissue samples.
“Pathology labs are navigating rising volumes, staffing shortages and growing calls for for precision, all whereas working with methods that haven’t meaningfully developed in a long time,” stated Thomas Tarnowski, Managing Director at Summit Companions.
“Dreampath’s platform is designed to deal with a key bottleneck within the pathology workflow. By enabling quick and traceable entry to tissue samples, the corporate is supporting extra constant lab operations and serving to enhance the standard of affected person care. We imagine Dreampath is well-positioned to guide the modernisation of pathology infrastructure on a worldwide scale,” he provides.
Dreampath has grown profitably and quickly at a CAGR of greater than 50% in recent times, pushed by what the corporate describes as a “sturdy demand” for its platform throughout the U.S., EMEA and different world markets.
Dreampath’s clients embody most cancers centres and industrial laboratories.
“We had been drawn to Dreampath due to their clear management in a fast-growing and more and more important phase of lab diagnostics,” added Jono Pagden, Principal at Summit Companions. “In our view, the corporate’s first-mover benefit, constant concentrate on high quality and powerful buyer adoption have helped Dreampath set up a robust status as a trusted supplier in digital archiving. We’re proud to be their first institutional accomplice and excited to assist the crew in scaling their affect globally.”
Together with the funding, each Thomas Tarnowski and Jono Pagden from Summit Companions have joined the Dreampath Board of Administrators.
